

16c1



FAX COVER SHEET

No. of pages incl. this: 3
Telefax no.: (703)308-4242
To: Examiner: Monshipouri, M.
From: Jason Garbell
Date: June 7, 2002
Message:

FAX RECEIVED
JUN 10 2002
GROUP 1600

OFFICIAL

Response to Restriction Requirement

The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.

**Novozymes
North America, Inc.**
Patents-US

500 Fifth Avenue,
Suite 1600
New York, NY 10110

Telephone:
(212) 840-0097, ext. 15
Telefax:
(212) 840-0221

email:
JGar@novozymes.com
internet:
www.novozymes.com

Attorney Docket No.: 5835.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FAX RECEIVED

In re Application of: Bisgård-Frantzen et al Confirmation No: 9183

JUN 10 2002

Serial No.: 09/710,339

Group Art Unit: 1652

GROUP 1600

Filed: November 9, 2000

Examiner: Monshipouri, M.

For: Fungamyl-like Alpha-Amylase Variants

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner
To be assigned, fax number (703) 308-4242.

Respectfully submitted,

Date: June 7, 2002


Julie Tabarovsky
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

OFFICIAL

Attorney Docket No.: 5835.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgård-Frantzen et al Confirmation No: 9183

Serial No.: 09/710,339

Group Art Unit: 1652

Filed: November 9, 2000

Examiner: Monshipouri, M.

For: Fungamyl-like Alpha-Amylase Variants

#15
D.G.J
6/11/02

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, DC 20231

Sir:


This paper is filed in response to the Office Action mailed May 7, 2002, that made a restriction requirement. Applicants were requested to elect one of seven designated groups.

In response to these requirements, Applicants hereby elect the invention of Group I. Applicants hereby reserve the right to file continuing applications directed to the non-elected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: June 6, 2002



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097